Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Transdermal Granisetron vs Ondansetron for CINV in HSCT
NCT04150614Phase 4Recruiting
- Sponsor
- University of Illinois Chicago
- Start
- May 2020
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Granisetron Hydrochloride Nasal Spray in chemotherapy-induced nausea and vomiting (CINV) (2 arms), sponsored by University of Illinois Chicago. Primary endpoint: Complete Response (no vomiting and no use of rescue medications) during the acute period. Started May 2020; status: recruiting.
02
Drugs
Granisetron Hydrochloride Nasal Spray
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT04150614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04150614.